Latest Insider Transactions at Tyra Biosciences, Inc. (TYRA)
This section provides a real-time view of insider transactions for Tyra Biosciences, Inc. (TYRA). The data is sourced from Form 4 filings with the SEC, which are filed by insiders of Tyra Biosciences, Inc. to disclose their transactions in the company's securities. By reviewing this information, investors can gain insights into the trading activity of Tyra Biosciences, Inc.'s insiders and make more informed investment decisions.
Insider Transaction List
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Mar 31
2023
|
Daniel Bensen Chief Operating Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
400
+0.08%
|
$0
$0.61 P/Share
|
|
Mar 31
2023
|
Todd Harris President and CEO |
SELL
Open market or private sale
|
Direct |
500
-0.03%
|
$8,000
$16.05 P/Share
|
|
Mar 31
2023
|
Todd Harris President and CEO |
BUY
Exercise of conversion of derivative security
|
Direct |
500
+0.03%
|
$1,000
$2.25 P/Share
|
|
Mar 30
2023
|
Daniel Bensen Chief Operating Officer |
SELL
Open market or private sale
|
Direct |
2,000
-0.38%
|
$32,000
$16.01 P/Share
|
|
Mar 30
2023
|
Daniel Bensen Chief Operating Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
2,000
+0.38%
|
$0
$0.61 P/Share
|
|
Mar 30
2023
|
Todd Harris President and CEO |
SELL
Open market or private sale
|
Direct |
2,407
-0.14%
|
$38,512
$16.02 P/Share
|
|
Mar 30
2023
|
Todd Harris President and CEO |
BUY
Exercise of conversion of derivative security
|
Direct |
2,407
+0.14%
|
$4,814
$2.25 P/Share
|
|
Mar 29
2023
|
Todd Harris President and CEO |
SELL
Open market or private sale
|
Direct |
1,420
-0.08%
|
$22,720
$16.18 P/Share
|
|
Mar 29
2023
|
Todd Harris President and CEO |
BUY
Exercise of conversion of derivative security
|
Direct |
1,420
+0.08%
|
$2,840
$2.25 P/Share
|
|
Mar 29
2023
|
Daniel Bensen Chief Operating Officer |
SELL
Open market or private sale
|
Direct |
2,187
-0.41%
|
$34,992
$16.21 P/Share
|
|
Mar 29
2023
|
Daniel Bensen Chief Operating Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
2,187
+0.41%
|
$0
$0.61 P/Share
|
|
Mar 28
2023
|
Daniel Bensen Chief Operating Officer |
SELL
Open market or private sale
|
Direct |
3,346
-0.63%
|
$53,536
$16.0 P/Share
|
|
Mar 28
2023
|
Daniel Bensen Chief Operating Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
3,346
+0.63%
|
$0
$0.61 P/Share
|
|
Mar 28
2023
|
Todd Harris President and CEO |
SELL
Open market or private sale
|
Direct |
2,779
-0.16%
|
$44,464
$16.0 P/Share
|
|
Mar 28
2023
|
Todd Harris President and CEO |
BUY
Exercise of conversion of derivative security
|
Direct |
2,779
+0.16%
|
$5,558
$2.25 P/Share
|
|
Mar 27
2023
|
Daniel Bensen Chief Operating Officer |
SELL
Open market or private sale
|
Direct |
8,048
-1.5%
|
$128,768
$16.0 P/Share
|
|
Mar 27
2023
|
Daniel Bensen Chief Operating Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
8,048
+1.48%
|
$0
$0.61 P/Share
|
|
Mar 27
2023
|
Todd Harris President and CEO |
SELL
Open market or private sale
|
Direct |
2,963
-0.17%
|
$47,408
$16.0 P/Share
|
|
Mar 27
2023
|
Todd Harris President and CEO |
BUY
Exercise of conversion of derivative security
|
Direct |
2,963
+0.17%
|
$5,926
$2.25 P/Share
|
|
Mar 24
2023
|
Todd Harris President and CEO |
SELL
Open market or private sale
|
Direct |
170
-0.01%
|
$2,720
$16.0 P/Share
|
|
Mar 24
2023
|
Todd Harris President and CEO |
BUY
Exercise of conversion of derivative security
|
Direct |
170
+0.01%
|
$340
$2.25 P/Share
|
|
Mar 23
2023
|
Daniel Bensen Chief Operating Officer |
SELL
Open market or private sale
|
Direct |
4,827
-0.91%
|
$77,232
$16.0 P/Share
|
|
Mar 23
2023
|
Daniel Bensen Chief Operating Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
4,827
+0.9%
|
$0
$0.61 P/Share
|
|
Mar 23
2023
|
Todd Harris President and CEO |
SELL
Open market or private sale
|
Direct |
2,800
-0.16%
|
$44,800
$16.0 P/Share
|
|
Mar 23
2023
|
Todd Harris President and CEO |
BUY
Exercise of conversion of derivative security
|
Direct |
2,800
+0.16%
|
$5,600
$2.25 P/Share
|
|
Mar 22
2023
|
Daniel Bensen Chief Operating Officer |
SELL
Open market or private sale
|
Direct |
3,800
-0.71%
|
$60,800
$16.0 P/Share
|
|
Mar 22
2023
|
Daniel Bensen Chief Operating Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
3,800
+0.71%
|
$0
$0.61 P/Share
|
|
Mar 22
2023
|
Todd Harris President and CEO |
SELL
Open market or private sale
|
Direct |
4,043
-0.24%
|
$64,688
$16.0 P/Share
|
|
Mar 22
2023
|
Todd Harris President and CEO |
BUY
Exercise of conversion of derivative security
|
Direct |
4,043
+0.24%
|
$8,086
$2.25 P/Share
|
|
Mar 21
2023
|
Daniel Bensen Chief Operating Officer |
SELL
Open market or private sale
|
Direct |
14,100
-2.6%
|
$225,600
$16.0 P/Share
|
|
Mar 21
2023
|
Daniel Bensen Chief Operating Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
14,100
+2.54%
|
$0
$0.61 P/Share
|
|
Mar 21
2023
|
Todd Harris President and CEO |
SELL
Open market or private sale
|
Direct |
12,393
-0.72%
|
$198,288
$16.0 P/Share
|
|
Mar 21
2023
|
Todd Harris President and CEO |
BUY
Exercise of conversion of derivative security
|
Direct |
12,393
+0.72%
|
$24,786
$2.25 P/Share
|
|
Mar 15
2023
|
Hiroomi Tada Chief Medical Officer |
BUY
Grant, award, or other acquisition
|
Direct |
1,893
+2.23%
|
$11,358
$6.58 P/Share
|
|
Mar 15
2023
|
Todd Harris President and CEO |
BUY
Grant, award, or other acquisition
|
Direct |
1,808
+0.11%
|
$10,848
$6.58 P/Share
|
|
Feb 21
2023
|
Piyush R. Patel Chief Development Officer |
SELL
Bona fide gift
|
Direct |
8,442
-10.27%
|
-
|
|
Feb 10
2023
|
Mva Investors, LLC |
SELL
Open market or private sale
|
Direct |
65,568
-74.43%
|
$852,384
$13.4 P/Share
|
|
Feb 09
2023
|
Mva Investors, LLC |
SELL
Open market or private sale
|
Direct |
200,000
-69.42%
|
$2,600,000
$13.1 P/Share
|
|
Oct 12
2022
|
Piyush R. Patel Chief Development Officer |
SELL
Bona fide gift
|
Direct |
56,276
-40.63%
|
-
|
|
Sep 15
2022
|
Esther Van Den Boom Chief Financial Officer |
BUY
Grant, award, or other acquisition
|
Direct |
1,452
+1.18%
|
$10,164
$7.66 P/Share
|
|
Sep 15
2022
|
Hiroomi Tada Chief Medical Officer |
BUY
Grant, award, or other acquisition
|
Direct |
612
+0.75%
|
$4,284
$7.66 P/Share
|
|
Sep 15
2022
|
Piyush R. Patel Chief Development Officer |
BUY
Grant, award, or other acquisition
|
Direct |
1,040
+0.75%
|
$7,280
$7.66 P/Share
|
|
Sep 15
2022
|
Robert L. Hudkins Chief Technology Officer |
BUY
Grant, award, or other acquisition
|
Direct |
1,040
+0.38%
|
$7,280
$7.66 P/Share
|
|
Mar 15
2022
|
Esther Van Den Boom Chief Financial Officer |
BUY
Grant, award, or other acquisition
|
Direct |
1,800
+1.47%
|
$14,400
$8.53 P/Share
|
|
Mar 15
2022
|
Hiroomi Tada Chief Medical Officer |
BUY
Grant, award, or other acquisition
|
Direct |
2,703
+3.24%
|
$21,624
$8.53 P/Share
|
|
Mar 15
2022
|
Ronald V. Swanson Chief Scientific Officer |
BUY
Grant, award, or other acquisition
|
Direct |
3,125
+1.13%
|
$25,000
$8.53 P/Share
|
|
Mar 15
2022
|
Piyush R. Patel Chief Development Officer |
BUY
Grant, award, or other acquisition
|
Direct |
2,408
+1.72%
|
$19,264
$8.53 P/Share
|
|
Mar 15
2022
|
Robert L. Hudkins Chief Technology Officer |
BUY
Grant, award, or other acquisition
|
Direct |
2,408
+0.88%
|
$19,264
$8.53 P/Share
|
|
Mar 15
2022
|
Todd Harris President and CEO |
BUY
Grant, award, or other acquisition
|
Direct |
3,125
+0.18%
|
$25,000
$8.53 P/Share
|
|
Dec 17
2021
|
Boxer Capital, LLC |
BUY
Open market or private purchase
|
Direct |
125,000
+1.9%
|
$1,625,000
$13.12 P/Share
|